December 8, 2025Blood

Real-world stratified treatment strategies in transplant-eligible newly diagnosed multiple myeloma: A multicohort study

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Multicohort analysis shows improved progression-free survival in transplant-eligible multiple myeloma based on risk profiles and therapies.

Mobilization success was achieved in every cohort indicating robust treatment approaches.
The ultrahigh-risk group achieved a median progression-free survival of 25 months with daratumumab-based therapy.
Complete response rates were high in both ultrahigh-risk and extramedullary cohorts, highlighting treatment efficacy.
Risk-adapted strategies support better outcomes across diverse multiple myeloma patient profiles.

Kuang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Multicohort analysis shows improved progression-free survival in transplant-eligible multiple myeloma based on risk profiles and therapies.

Mobilization success was achieved in every cohort indicating robust treatment approaches.
The ultrahigh-risk group achieved a median progression-free survival of 25 months with daratumumab-based therapy.
Complete response rates were high in both ultrahigh-risk and extramedullary cohorts, highlighting treatment efficacy.
Risk-adapted strategies support better outcomes across diverse multiple myeloma patient profiles.

Kuang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark